MAVIRET® (glecaprevir/pibrentasvir) Approved by Health Canada for Paediatric Patients with Chronic Hepatitis C
MAVIRET can now be used as an 8-week, once-daily paediatric granule formulation option in treatment-naïve, without cirrhosis or with compensated cirrhosis, chronic Hepatitis C paediatric... | June 22, 2022
Glecaprevir Pibrentasvir Jennifer Van Gennip Tracey Ramsay Division Of Gastroenterology Canadian Network On Hepatitisc Canhep World Health Organization
Source: marketscreener.com